APO-RIVASTIGMINE PATCH 5 rivastigmine 4.6 mg/24 hours transdermal drug delivery system sachet

País: Austrália

Língua: inglês

Origem: Department of Health (Therapeutic Goods Administration)

Ingredientes ativos:

rivastigmine, Quantity: 9 mg

Disponível em:

Arrotex Pharmaceuticals Pty Ltd

DCI (Denominação Comum Internacional):

Rivastigmine

Forma farmacêutica:

Drug delivery system, transdermal

Composição:

Excipient Ingredients: acrylates copolymer; ethyl acetate; hexane; 2-ethylhexyl acrylate; methyl acrylate; acrylic acid; acrylates/ethylhexyl acrylate copolymer; methylated trimethylated silica

Via de administração:

Transdermal

Unidades em pacote:

7 transdermal drug delivery systems, 30 transdermal drug delivery systems

Tipo de prescrição:

(S4) Prescription Only Medicine

Indicações terapêuticas:

APO-RIVASTIGMINE is indicated for the treatment of patients with mild to moderate dementia of the Alzheimer's type.

Resumo do produto:

Visual Identification: Circular 5cm2 transdermal patch, tri-layer adhesive matrix, translucent white backing film labelled with "Rivastigmine 4.6 mg/24 h"; Container Type: Sachet; Container Material: Other composite material; Container Life Time: 24 Months; Container Temperature: Store below 25 degrees Celsius

Status de autorização:

Licence status A

Data de autorização:

2016-01-12